{"organizations": [], "uuid": "036d9b791e6fc6662996704ecc489742cd4e9207", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-gw-pharma-says-mid-stage-study-of/brief-gw-pharma-says-mid-stage-study-of-seizures-drug-failed-main-goal-idUSFWN1QB0YM", "country": "US", "domain_rank": 408, "title": "BRIEF-GW Pharma Says Mid Stage Study Of Seizures Drug Failed Main Goal", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T23:11:00.000+02:00", "replies_count": 0, "uuid": "036d9b791e6fc6662996704ecc489742cd4e9207"}, "author": "", "url": "https://www.reuters.com/article/brief-gw-pharma-says-mid-stage-study-of/brief-gw-pharma-says-mid-stage-study-of-seizures-drug-failed-main-goal-idUSFWN1QB0YM", "ord_in_thread": 0, "title": "BRIEF-GW Pharma Says Mid Stage Study Of Seizures Drug Failed Main Goal", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-gw pharma says mid stage study of seizures drug", "sentiment": "negative"}, {"name": "brief-gw pharma says mid stage study of seizure", "sentiment": "negative"}, {"name": "gw pharmaceuticals plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gw pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 9:12 PM / Updated 13 minutes ago BRIEF-GW Pharma Says Mid Stage Study Of Seizures Drug Failed Main Goal Reuters Staff Feb 21 (Reuters) - GW Pharmaceuticals Plc: * GW PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS OF PHASE 2A STUDY FOR ITS PIPELINE COMPOUND GWP42006 * GW PHARMA - PHASE 2A PROOF OF CONCEPT STUDY OF A PIPELINE COMPOUND GWP42006 IN ADULT PATIENTS WITH FOCAL SEIZURES DID NOT MEET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T23:11:00.000+02:00", "crawled": "2018-02-21T23:34:00.049+02:00", "highlightTitle": ""}